New market study, "NPS+ Psoriasis (EU5)", has been published

Psoriasis: NPS results for psoriasis treatments show clear winners and losers. How does your brand rank?

Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of satisfaction among treatments available. When observed in comparison to the US, it is clear that Europe sees a much larger range of NPS results across the available brands. This makes it even more critical to know what brand messages are being associated with your brands, what effect this has on physicians' recommendations, and most importantly, how your brand compares to your competitors.

Full Report Details at
- http://www.fastmr.com/prod/1180412_nps+_psoriasis_eu5.aspx?afid=301

FirstView's NPS+ Psoriasis report compares brand loyalty for 8 major psoriasis treatments-information you can use to improve your brand's health, and boost your market share.

Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand-and your competitors. Plus you'll learn which brand messages drive recommendations, and get candid thoughts about your brand from prescribing dermatologists.

Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.

Reasons to Get this Report

Get Answers to Key Questions about Psoriasis Treatments

* Humira (adalimumab; AbbVie): Strong NPS results, but is the long term efficacy & safety of the brand affecting recommendations?
* Stelara (ustekinumab; Janssen Biotech): Scoring above the mean average for loyalty, but what one factor is stopping the detractors from recommending the treatment?
* Cosentyx (secukinumab; Novartis): Promoters of Cosentyx promote the least number of other brands & physicians feedback is very positive, but how does it rank?
* Enbrel (etanercept; Pfizer): Could Enbrel benefit from pushing its risk profile more to physicians?
* Remicade (infliximab; MSD): Promoter numbers are evenly matched with Enbrel, but who stands to gain more from converting their detractors to promoters?
* Otezla (apremilast; Celgene): Which drugs do physicians consider interchangeable with Otezla?
* Inflectra (infliximab; Pfizer): Are detractors showing scepticism due to it being a biosimilar?
* Remsima (infliximab; Napp/Mundipharma): Which of the EU5 countries shows the most positive feedback from physicians about Remsima?

Top Takeaways

* Brands fall across a sliding scale: NPS results show a clear winner, but the range of scores makes it imperative to know where your brand is in the pecking order.
* Brand with highest NPS doesn't have the most promoters: Find out why two close competitors have similar or higher numbers of promoters, but much lower scores.
* Almost 15% lower satisfaction than US: Due to the availability of biosimilars, the EU5 sees a larger selection of drugs available. Find out what effect biosimilars have on the overall score.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS+ Psoriasis (US)
- NPS+ Renal Cell Carcinoma (EU5)
- NPS+ HIV (EU5)
- NPS+ Asthma/COPD (EU5)
- Market Access Impact: Psoriasis (EU5)